DE69231081D1 - Verbesserte thrombininhibitoren - Google Patents

Verbesserte thrombininhibitoren

Info

Publication number
DE69231081D1
DE69231081D1 DE69231081T DE69231081T DE69231081D1 DE 69231081 D1 DE69231081 D1 DE 69231081D1 DE 69231081 T DE69231081 T DE 69231081T DE 69231081 T DE69231081 T DE 69231081T DE 69231081 D1 DE69231081 D1 DE 69231081D1
Authority
DE
Germany
Prior art keywords
substituted
atoms
bond
group
backbone chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231081T
Other languages
English (en)
Other versions
DE69231081T2 (de
Inventor
M Maraganore
M Jablonski
R Bourdon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of DE69231081D1 publication Critical patent/DE69231081D1/de
Application granted granted Critical
Publication of DE69231081T2 publication Critical patent/DE69231081T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Manipulator (AREA)
DE69231081T 1991-02-08 1992-02-03 Verbesserte thrombininhibitoren Expired - Lifetime DE69231081T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/652,929 US5240913A (en) 1989-08-18 1991-02-08 Inhibitors of thrombin
PCT/US1992/000836 WO1992013952A1 (en) 1991-02-08 1992-02-03 Improved inhibitors of thrombin

Publications (2)

Publication Number Publication Date
DE69231081D1 true DE69231081D1 (de) 2000-06-29
DE69231081T2 DE69231081T2 (de) 2001-02-01

Family

ID=24618783

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231081T Expired - Lifetime DE69231081T2 (de) 1991-02-08 1992-02-03 Verbesserte thrombininhibitoren

Country Status (19)

Country Link
US (3) US5240913A (de)
EP (1) EP0529031B9 (de)
JP (1) JPH05506252A (de)
KR (1) KR100259759B1 (de)
AT (1) ATE193325T1 (de)
AU (1) AU659828B2 (de)
BG (1) BG61243B2 (de)
CA (1) CA2079778C (de)
DE (1) DE69231081T2 (de)
DK (1) DK0529031T3 (de)
ES (1) ES2149170T3 (de)
FI (2) FI120348B (de)
GR (1) GR3034257T3 (de)
HK (1) HK1005995A1 (de)
HU (1) HU218831B (de)
NO (1) NO315710B1 (de)
NZ (1) NZ241557A (de)
TW (1) TW222642B (de)
WO (1) WO1992013952A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240913A (en) * 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US6060451A (en) * 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5458568A (en) * 1991-05-24 1995-10-17 Cortrak Medical, Inc. Porous balloon for selective dilatation and drug delivery
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5599307A (en) * 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
JPH09504554A (ja) * 1993-12-27 1997-05-06 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント，インコーポレーテッド 血栓形成を阻止する方法及び組成物
AU1562895A (en) * 1994-01-12 1995-08-01 Massachusetts Institute Of Technology Process for making xanthene or cubane based compounds, and protease inhibitors
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5849510A (en) * 1994-04-26 1998-12-15 Selectide Corporation Factor Xa inhibitors
US6759384B1 (en) 1994-04-26 2004-07-06 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5747453A (en) * 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
DE19549118C2 (de) * 1995-12-29 2000-07-13 Thomas W Stief Hämostaseaktivierungs-Inhibitor und Verfahren zum Hemmen der Hämostaseaktivierung in Blut oder anderen biologischen Flüssigkeiten
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
JPH1010784A (ja) * 1996-06-27 1998-01-16 Brother Ind Ltd 正帯電性一成分現像剤並びにその現像剤を用いた画像形成装置
GB9613719D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Serine protease inhibitors
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
DE10162521A1 (de) * 2001-12-19 2003-07-17 Goetz Nowak Verwendung von molekulargewichtserweiterten Substanzen in der Tumortherapie
DE602005023429D1 (de) 2004-10-19 2010-10-21 Lonza Ag Verfahren zur festphasen-peptidsynthese
US7598343B1 (en) 2008-07-27 2009-10-06 The Medicines Company Pharmaceutical formulations of bivalirudin and processes of making the same
US7582727B1 (en) 2008-07-27 2009-09-01 The Medicinces Company Pharmaceutical formulations of bivalirudin and processes of making the same
EP2349307B1 (de) * 2008-09-03 2015-03-04 ScinoPharm Taiwan, Ltd. Verfahren zur herstellung von bivalirudin
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
RS63143B1 (sr) 2016-06-01 2022-05-31 Athira Pharma Inc Jedinjenja
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1161431A (en) * 1979-05-11 1984-01-31 Lars G. Svendsen Tripeptide derivatives
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
DE3501107A1 (de) * 1985-01-15 1986-07-17 Josef 8358 Vilshofen Paul Nutzfahrzeug mit schieberahmenwechselaufbau
CA1341032C (en) * 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
CA1340646C (en) * 1987-05-21 1999-07-13 John L. Krstenansky Cyclic anticoagulant peptides
ZA883444B (de) * 1987-05-21 1988-11-16
AU3098289A (en) * 1988-03-04 1989-09-07 Biogen, Inc. Hirudin peptides
US4971953A (en) * 1988-05-10 1990-11-20 Merrell Dow Pharmaceuticals Anticoagulant peptide alcohols
NZ228995A (en) * 1988-05-10 1992-03-26 Merrell Dow Pharma Hirudin peptide derivatives and pharmaceutical compositions
WO1990003391A1 (en) * 1988-09-29 1990-04-05 Biogen, Inc. Hirudin peptides
US5240913A (en) * 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
JP2669510B2 (ja) * 1990-06-15 1997-10-29 ナショナル・リサーチ・カウンシル・オブ カナダ ヒルジンのアミノ酸配列に基づくトロンビン阻害剤

Also Published As

Publication number Publication date
AU1362192A (en) 1992-09-07
NO315710B1 (no) 2003-10-13
FI924503A0 (fi) 1992-10-06
HU9203500D0 (en) 1993-01-28
HUT65675A (en) 1994-07-28
US5425936A (en) 1995-06-20
ATE193325T1 (de) 2000-06-15
EP0529031A1 (de) 1993-03-03
FI120690B (fi) 2010-01-29
US5240913A (en) 1993-08-31
FI924503A (fi) 1992-10-06
KR100259759B1 (ko) 2000-06-15
DK0529031T3 (da) 2000-10-09
CA2079778C (en) 2002-09-03
NO923889D0 (no) 1992-10-07
JPH05506252A (ja) 1993-09-16
FI120348B (fi) 2009-09-30
TW222642B (de) 1994-04-21
ES2149170T3 (es) 2000-11-01
EP0529031B9 (de) 2007-11-21
HU218831B (hu) 2000-12-28
AU659828B2 (en) 1995-06-01
CA2079778A1 (en) 1992-08-09
DE69231081T2 (de) 2001-02-01
GR3034257T3 (en) 2000-12-29
HK1005995A1 (en) 1999-02-05
FI20050027A (fi) 2005-01-11
BG61243B2 (bg) 1997-03-31
NO923889L (no) 1992-12-08
WO1992013952A1 (en) 1992-08-20
US5514409A (en) 1996-05-07
EP0529031B1 (de) 2000-05-24
NZ241557A (en) 1996-11-26

Similar Documents

Publication Publication Date Title
DE69231081D1 (de) Verbesserte thrombininhibitoren
US5196404B1 (en) Inhibitors of thrombin
NO20041494L (no) Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form
WO1999032100A3 (en) Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
WO1996031531A3 (en) Fluorescent peptides
YU69699A (sh) Derivati aril karbonske kiseline i tetrazola
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
TR199701066T1 (xx) Sikloheksilamino- ve-alkoksi -azot-heterosiklenler.
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
BR9913526A (pt) Métodos de tratamento da osteoartrite com inibidores de sintase de óxido nìtrico induzìvel
DK1826214T3 (da) Sammensætning omfattende ferrocen-derivater og brændstofsammensætning omfattende sådanne derivater
ATE374180T1 (de) N-acylpyrrolidin-2-ylalkylbenzamidin-derivate als inhibitoren von factor xa
DE602004020971D1 (de) Schlammbehandlung
SE9704723D0 (sv) Ligands
FR2787793B1 (fr) Composes pseudopeptidiques dotes d'une activite inhibitrice a l'egard des voies activees par les proteines a activite tyrosine kinase et les compositions pharmaceutiques les contenant
RU94030475A (ru) Новые производные пептидов, способ получения, фармацевтическая композиция, способ лечения, промежуточные соединения
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii
TH39469A3 (th) สารประกอบไซคลิกเอไมด์

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US